ABBREVIATIONS:

AE, adverse event; G-CSF, granulocyte-colony stimulating factor.

REFERENCES:

1. TRODELVY (sacituzumab govitecan) Summary of Product Characteristics, June 2025. 2. Bardia A, et al. N Engl J Med. 2021;384(16):1529–1541. 3. Rugo H, et al. NPJ Breast Cancer. 2022; 8: 98.doi: 10.1038/s41523-022-00467-1.